WO2006114065A3 - Use of compounds to inhibit neoplasia - Google Patents

Use of compounds to inhibit neoplasia Download PDF

Info

Publication number
WO2006114065A3
WO2006114065A3 PCT/CZ2006/000024 CZ2006000024W WO2006114065A3 WO 2006114065 A3 WO2006114065 A3 WO 2006114065A3 CZ 2006000024 W CZ2006000024 W CZ 2006000024W WO 2006114065 A3 WO2006114065 A3 WO 2006114065A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inhibit neoplasia
neoplasia
inhibit
processivity
Prior art date
Application number
PCT/CZ2006/000024
Other languages
French (fr)
Other versions
WO2006114065A2 (en
Inventor
Miroslav Hajek
Nadezda Matulova
Ivan Votruba
Antonin Holy
Eva Tloustova
Original Assignee
Acad Of Science Czech Republic
Miroslav Hajek
Nadezda Matulova
Ivan Votruba
Antonin Holy
Eva Tloustova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acad Of Science Czech Republic, Miroslav Hajek, Nadezda Matulova, Ivan Votruba, Antonin Holy, Eva Tloustova filed Critical Acad Of Science Czech Republic
Publication of WO2006114065A2 publication Critical patent/WO2006114065A2/en
Publication of WO2006114065A3 publication Critical patent/WO2006114065A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides the use of acyclic nucleoside phosphonates and their derivatives for the manufacture of a medicament for inhibiting an enzyme that causes neoplasia in an animal (e.g. a human) and enhancing the processivity of a telomerase.
PCT/CZ2006/000024 2005-04-25 2006-04-25 Use of compounds to inhibit neoplasia WO2006114065A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67446605P 2005-04-25 2005-04-25
US60/674,466 2005-04-25
US67523505P 2005-04-27 2005-04-27
US67523405P 2005-04-27 2005-04-27
US60/675,235 2005-04-27
US60/675,234 2005-04-27

Publications (2)

Publication Number Publication Date
WO2006114065A2 WO2006114065A2 (en) 2006-11-02
WO2006114065A3 true WO2006114065A3 (en) 2007-06-28

Family

ID=36778204

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CZ2006/000023 WO2006114064A2 (en) 2005-04-25 2006-04-25 Use of compounds to enhance processivity of telomerase
PCT/CZ2006/000024 WO2006114065A2 (en) 2005-04-25 2006-04-25 Use of compounds to inhibit neoplasia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CZ2006/000023 WO2006114064A2 (en) 2005-04-25 2006-04-25 Use of compounds to enhance processivity of telomerase

Country Status (5)

Country Link
EP (1) EP1879657A2 (en)
JP (1) JP2008538771A (en)
AU (1) AU2006239677A1 (en)
CA (1) CA2606399A1 (en)
WO (2) WO2006114064A2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2908133B1 (en) * 2006-11-08 2012-12-14 Centre Nat Rech Scient NOVEL NUCLEOTIDE ANALOGUES AS ANTIVIRAL PRECURSOR MOLECULES
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
DK2794624T3 (en) * 2011-12-22 2019-07-22 Geron Corp Guanine analogues such as telomerase substrates and telomere length influencers
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
CN104995192A (en) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Modulation of IRE1
AU2014228321C1 (en) * 2013-03-15 2019-07-11 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
CN105338987A (en) 2013-04-08 2016-02-17 得克萨斯系统大学评议会 Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691872A1 (en) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
HRP20220651T1 (en) 2014-09-15 2022-08-19 The Regents Of The University Of California Nucleotide analogs
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN114230571A (en) 2015-09-14 2022-03-25 无限药品股份有限公司 Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7054681B2 (en) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド Combination therapy
RU2759902C2 (en) 2016-12-22 2021-11-18 Мерк Шарп И Доум Корп. Antiviral aliphatic ester prodrugs of tenofovir
CN108948084B (en) * 2017-05-19 2020-10-20 浙江司太立制药股份有限公司 Tenofovir di-L-amino acid ester and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003467A2 (en) * 1992-08-05 1994-02-17 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EP0618214A1 (en) * 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
WO2000074667A2 (en) * 1999-06-04 2000-12-14 Au Jessie L S Compositions active in telomere damage comprising a taxane and telomerase inhibitor
WO2001039724A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California, San Diego Phosphonate compounds
US20020169140A1 (en) * 2001-03-06 2002-11-14 Prendergast Patrick T. Combination therapy for reduction of toxicity of chemotherapeutic agents
EP1418241A1 (en) * 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
WO2005072748A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003467A2 (en) * 1992-08-05 1994-02-17 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EP0618214A1 (en) * 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
WO2000074667A2 (en) * 1999-06-04 2000-12-14 Au Jessie L S Compositions active in telomere damage comprising a taxane and telomerase inhibitor
WO2001039724A2 (en) * 1999-12-03 2001-06-07 The Regents Of The University Of California, San Diego Phosphonate compounds
US20020169140A1 (en) * 2001-03-06 2002-11-14 Prendergast Patrick T. Combination therapy for reduction of toxicity of chemotherapeutic agents
EP1418241A1 (en) * 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
WO2005072748A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAJEK ET AL: "Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 70, no. 6, 15 September 2005 (2005-09-15), pages 894 - 900, XP005025018, ISSN: 0006-2952 *
HOLY A: "PHOSPHONOMETHOXYALKYL ANALOGS OF NUCLEOTIDES", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 9, December 2003 (2003-12-01), pages 2567 - 2592, XP008058387, ISSN: 1381-6128 *
OTOVA BERTA ET AL: "Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP", IN VIVO (ATTIKI), vol. 11, no. 2, 1997, pages 163 - 167, XP009071002, ISSN: 0258-851X *
ROSE W C ET AL: "IN-VIVO ANTITUMOR ACTIVITY OF 9-2 PHOSPHONYLMETHOXYETHYLGUANINE AND RELATED PHOSPHONATE NUCLEOTIDE ANALOGUES", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 82, no. 6, 1990, pages 510 - 512, XP009071006, ISSN: 0027-8874 *
VALERIANOVA MARIE ET AL: "Antitumour activity of N6-substituted PMEDAP derivatives against T-cell lymphoma", ANTICANCER RESEARCH, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2057 - 2064, XP009071015, ISSN: 0250-7005 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
AU2006239677A1 (en) 2006-11-02
EP1879657A2 (en) 2008-01-23
CA2606399A1 (en) 2006-11-02
WO2006114064A2 (en) 2006-11-02
WO2006114064A3 (en) 2007-06-28
JP2008538771A (en) 2008-11-06
WO2006114065A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2006114065A3 (en) Use of compounds to inhibit neoplasia
NO20084882L (en) Crystalline forms A and B of a maleate salt of 5-amino-3- (2'3'-di-o-acetyl-beta-D-ribofuranosyl) -3H-thiazolo [4,5-d] pyrimidin-2 one
WO2008076883A3 (en) Triazine derivatives and their therapeutical applications
NI201100007A (en) CHEMICAL COMPOUNDS 251.
MX2009013729A (en) Imidazopyrazines as protein kinase inhibitors.
MX2009012066A (en) Substituted imidazopyridazines as pi3k lipid kinase inhibitors.
TW200801008A (en) Protein kinase inhibitors
DK2004641T3 (en) HIV inhibiting 5- (hydroxymethylene and aminomethylene) substituted pyrimidines
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
EA200802118A1 (en) HAVING INHIBITING ACTIVITY WITH RESPECT TO MNK1 / MNK2 THYENOPYRIMIDINES INTENDED FOR USE IN PHARMACEUTICAL COMPOSITIONS
MX2009004623A (en) Imidazopyridazines as pi3k lipid kinase inhibitors.
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
UA95464C2 (en) Pyridopyrazine derivatives and use thereof
ECSP088906A (en) PIRAZOLO 1,5-a PYRIMIDINS
MX2009003734A (en) Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor.
WO2011075665A3 (en) Beta-cell replication promoting compounds and methods of their use
WO2005074925A8 (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
WO2007075923A3 (en) Treatment of synucleinopathies
WO2008046865A3 (en) Long-term feed - elderly
MX2008011576A (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs.
TW200738723A (en) 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2006081337A3 (en) Erastin analogues and their uses for killing cancer cells
WO2008051421A3 (en) Peptide-cytotoxic conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06722451

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6722451

Country of ref document: EP